Midv-075

The relatively benign phenotype of MIDV‑075 in mammals, coupled with its ability to elicit a robust interferon response, makes it an attractive for delivering recombinant antigens. Its genome can be engineered to replace the structural E‑gene with antigens from high‑priority pathogens (e.g., SARS‑CoV‑2 RBD), while preserving replication competence in target cells. Preliminary data from a chimeric MIDV‑075‑E‑GFP construct show stable expression and immunogenicity in murine models without overt pathology.

: Evaluate the performances of the actors. Consider their chemistry, acting skills, and how they engage with the content. MIDV-075